Video
Expert: Psychedelic Medicine Will Lead to a Massive Paradigm Shift for Mental Health Treatment
Payton Nyquvest, CEO and founder of Numinus, said he believes psychedelic medicines will lead to a significant shift in the mental health treatment landscape in the next 3 to 5 years.
In an interview with Pharmacy Times, Payton Nyquvest, CEO and founder of Numinus, said he believes psychedelic medicines will lead to a significant shift in the mental health treatment landscape in the next 3 to 5 years.
The lab at Numinus is one of the first labs licensed to produce, sell, export, and deliver a variety of psychedelic compounds and natural source materials, Nyquvest said. In the interview, he discussed the future of regulations around psychedelic compounds, the importance of new treatments for mental health, and plans to support greater access to psychedelic-assisted therapies.
FDA Approves Bimekizumab-Bkzx as Treatment for Hidradenitis Suppurativa
FDA Approves Eladocagene Exuparvovec-Tneq for Treatment of AADC Deficiency
